Literature DB >> 9044506

Molecular pathology of posttransplantation lymphoproliferative disorders.

A Chadburn1, E Cesarman, D M Knowles.   

Abstract

Posttransplantation lymphoproliferative disorders (PT-LPDs) represent a heterogeneous group of Epstein-Barr virus (EBV) associated lymphoid proliferations occurring in the setting of immunosuppression associated with solid organ transplantation. Some PT-LPDs regress after a reduction in immunosuppression, whereas others progress despite aggressive therapy. Previously defined histopathologic categories do not correlate with clonality, and neither histopathology nor clonality has reliably predicted their clinical behavior. Recently, correlative clinical, morphological, and molecular genetic analysis has suggested that PT-LPDs are divisible into three distinct clinically relevant categories as follows: (1) plasmacytic hyperplasia: most commonly arise in the oropharynx or lymph nodes, are nearly always polyclonal, usually contain multiple EBV infectious events or only a minor cell population infected by a single form of EBV, and lack oncogene or tumor suppressor gene alterations; (2) polymorphic lymphoproliferative disorders: may arise in lymph nodes or extranodal sites including the gastrointestinal tract and lungs, are nearly always monoclonal based on the presence of clonal immunoglobulin gene rearrangements, usually contain a single form of EBV, and lack oncogene or tumor suppressor gene alterations; and (3) malignant lymphoma or multiple myeloma: present with widely disseminated disease frequently including the bone marrow, are monoclonal based on clonal immunoglobulin gene rearrangements, contain a single form of EBV, and contain alterations of one or more oncogenes or tumor suppressor genes (c-myc, ras, p53). Thus, proto-oncogene and tumor suppressor gene alterations appear to be associated with disease progression and an often fatal clinical outcome. Furthermore, multiple PT-LPD lesions occurring in the same individual but in multiple anatomic sites, either simultaneously or dysynchronously over time, may show distinct clonal immunoglobulin gene rearrangement patterns and evidence of infection by different forms of EBV, suggesting that each lesion represents a distinct clonal neoplasm that may show distinctive clinical behavior. Therefore, whenever possible, a biopsy of each one of the several PT-LPD lesions occurring in an individual should be obtained to derive a true assessment of the pathobiological nature and clinical aggressiveness of an individual's disease.

Entities:  

Mesh:

Year:  1997        PMID: 9044506

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  15 in total

1.  Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis.

Authors:  Q Tao; L J Swinnen; J Yang; G Srivastava; K D Robertson; R F Ambinder
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

Review 2.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 3.  Molecular diagnosis of Epstein-Barr virus-related diseases.

Authors:  M L Gulley
Journal:  J Mol Diagn       Date:  2001-02       Impact factor: 5.568

Review 4.  Where are we at with short bowel syndrome and small bowel transplant.

Authors:  Baris Dogu Yildiz
Journal:  World J Transplant       Date:  2012-12-24

5.  Lymphoid tissues from patients with infectious mononucleosis lack monoclonal B and T cells.

Authors:  Julie A Plumbley; Hongxin Fan; Phyllis A Eagan; Aamir Ehsan; Bertram Schnitzer; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2002-02       Impact factor: 5.568

6.  Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy.

Authors:  Qian Tao; Jie Yang; He Huang; Lode J Swinnen; Richard F Ambinder
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 7.  Interferon-alpha and its effects on post-transplant lymphoproliferative disorders.

Authors:  A Faro
Journal:  Springer Semin Immunopathol       Date:  1998

Review 8.  Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD).

Authors:  M A Nalesnik
Journal:  Springer Semin Immunopathol       Date:  1998

Review 9.  The molecular genetics of post-transplantation lymphoproliferative disorders.

Authors:  D M Knowles
Journal:  Springer Semin Immunopathol       Date:  1998

10.  Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient.

Authors:  Ninette Amariglio; Abraham Hirshberg; Bernd W Scheithauer; Yoram Cohen; Ron Loewenthal; Luba Trakhtenbrot; Nurit Paz; Maya Koren-Michowitz; Dalia Waldman; Leonor Leider-Trejo; Amos Toren; Shlomi Constantini; Gideon Rechavi
Journal:  PLoS Med       Date:  2009-02-17       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.